News

Morningstar24d
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
Efficacy results of Ipsen’s Phase 2 ELMWOOD trial (LB25222/OS089 ... since June 2024 for the treatment of Primary Biliary Cholangitis (PBC), was developed by GENFIT, from initial discovery ...